

Angiotensin-converting enzyme I/D polymorphism and susceptibility of psoriasis.

Min Huang¹, Guo-Dong Huang², Dan Peng³

¹Department of TCM Dermatology, Jiangxi children's Hospital, Nanchang 330000, Jiangxi, P.R. China

²Department of Integration of Traditional and Western Medicine, First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, P.R. China

³Department of Pharmacy, Jiangxi Children's Hospital, Nanchang 330000, Jiangxi, P.R. China

Abstract

The role of angiotensin-converting enzyme (ACE) I/D polymorphism in psoriasis have not been determined. Thus, in this study, we aimed to analyse ACE I/D polymorphism for the association with the risk of psoriasis in a Chinese Han population. A total of 161 cases (72 men and 89 women; mean age, 43.8 ± 5.5 years) and 256 controls (119 men and 137 women; mean age, 42.1 ± 6.9 years) were included in the study. The observed frequencies of all tested genotypes in controls did not deviate from Hardy-Weinberg equilibrium (HWE). Compared with the II genotype, the DD frequency of ACE I/D polymorphism among cases was significantly different from controls (DD versus II: OR=2.94; 95% CI=1.61-5.42; $p<0.05$). In addition, compared with the I allele, the D allele among cases was significantly associated with psoriasis risk (D versus I: OR=1.61; 95% CI=1.21-2.21; $p<0.05$). In conclusion, the current study showed that ACE I/D polymorphism may influence the risk of psoriasis in a Chinese Han population.

Keywords: Psoriasis; Angiotensin-converting enzyme; Polymorphism.

Accepted on April 28, 2017

Introduction

Psoriasis is a dynamic systemic disease that can have a profound effect on a patient's self-esteem [1]. It characterized by a chronic, autoimmune, and complex genetic disorder [2]. The burden of the disease is not limited solely to the skin, with an estimated 30% patients developing psoriatic arthritis, which in its most aggressive form can cause permanent joint damage [3].

Angiotensin-converting enzyme (ACE) is a key player in the renin-angiotensin system (RAS). ACE levels in plasma and tissue are under genetic control [4]. Rigat et al. found that approximately 50% of ACE plasma level variability was associated with I/D gene polymorphism [4]. ACE D allele carriers have higher ACE plasma [5] and tissue [6] levels compared with those with ID and II genotypes. The role of ACE I/D polymorphism in psoriasis has not been determined. Thus, in this study, we aimed to analyze ACE I/D polymorphism for the association with the risk of psoriasis in a Chinese Han population.

Methods

Study subjects

A total of 161 patients and 256 healthy controls were enrolled for this case-control study. Individuals who came to the hospital for routine physical examination were recruited as health controls. The characteristics of each subject, including age and gender, were collected via a questionnaire. For patients, the clinical features were collected from the patients' medical records. The study protocol was approved by the Institutional Review Boards of the hospital.

Genotyping

DNA was extracted from whole blood samples by salting out method. Target DNA regions of the ACE gene were amplified by allele-specific polymerase chain reaction. The sequence of primers used for amplification of ACE was 5'-CTGGAGACCACTCCCATCCTTTCT-3' (forward) and 5'-GATGTCGCCATCACATTCGTCAGAT-3' (reverse). Amplification of the I allele is sometimes suppressed in ID genotype samples giving rise to mistyping of ID as DD in approximately 5 % of cases. To avoid such mistyping, samples of the DD genotype were subjected to a second independent PCR with primers that recognize an insertion-specific

sequence: 5'-TGGGACCACAGCGCCCGCCACTAC-3' (forward) and 5'-TCGCCAGCCCTCCCATGCCATAA-3' (reverse). The reaction mixture consist of template DNA 3 μ l, each of primer 1 μ l, primers (i-Taq) 5 μ l, and distilled water 14 μ l. Procedure consisted of initial denaturation at 94°C for 5 min, then denaturation at 94°C for 35 s, annealing at 56°C for 40 s, and extension at 72°C for 1 min, repeated for 35 cycles, and followed by a final extension at 72°C for 8 min.

Statistical analysis

All statistical analyses were performed by the Statistical Package for Social Sciences for Windows software (Windows version release 18.0; SPSS, Inc., Chicago, IL, USA). The frequencies of allele and genotype in cases and controls were calculated by gene counting method. Differences between cases and controls in demographic characteristics and frequencies of genotypes were evaluated by using chi-square (χ^2) test. Hardy-Weinberg equilibrium (HWE) was also tested by a chi-square (χ^2) test. Differences were considered significant when $P < 0.05$.

Results

A total of 161 cases (72 men and 89 women; mean age, 43.8 ± 5.5 years) and 256 controls (119 men and 137 women; mean age, 42.1 ± 6.9 years) were included in the study. The demographic data of all participants are summarized in Table 1. There was no significant difference in age ($p > 0.05$) and sex ($p > 0.05$) between cases and controls. For the family history, 104 (64.4%) patients had family history. Most of the patients (66.2%) had psoriasis area and severity index less than 20.

Table 1. Clinical characteristics of the psoriasis patients (cases) and controls.

Characteristics	Case (%)	Control (%)	P value
Age	43.8 ± 5.5	42.1 ± 6.9	>0.05
Gender			
Female	89 (55.6%)	137 (53.7%)	>0.05
Male	72 (44.4%)	119 (46.3%)	
Family history			
Yes	104 (64.4%)		
No	57 (35.6%)		
PASI			
>20	54 (33.8%)		
<20	107 (66.2%)		

PASI: Psoriasis Area and Severity Index

The genotype distributions of the polymorphism in cases and controls are presented in Table 2. The observed frequencies of all tested genotypes in controls did not deviate from Hardy-Weinberg equilibrium (HWE). Compared with the II genotype, the DD frequency of ACE I/D polymorphism among cases was

significantly different from controls (DD versus II: OR=2.94; 95% CI=1.61-5.42; $p < 0.05$). In addition, compared with the I allele, the D allele among cases was significantly associated with psoriasis risk (D versus I: OR=1.61; 95% CI=1.21-2.21; $p < 0.05$).

Table 2. Genotype distribution and allele frequencies of ACE I/D polymorphism between psoriasis patients (cases) and controls.

	Case (%)	Control (%)	OR (95%CI)	P value
Genotype				
II	55 (34.2%)	119 (46.5%)	1 (Ref.)	
ID	71 (44.1%)	111 (43.4%)	1.34 (0.85-2.04)	>0.05
DD	35 (21.7%)	26 (10.1%)	2.94 (1.61-5.42)	<0.05
Allele				
I	181 (56.2%)	349 (68.2%)	1 (Ref.)	
D	141 (43.8%)	163 (31.8%)	1.61 (1.21-2.21)	<0.05

Discussion

In the present study the possible association between ACE I/D polymorphism and the risk of psoriasis was investigated. Compared with the II genotype, the DD frequency of ACE I/D polymorphism among cases was significantly different from controls. In addition, compared with the I allele, the D allele among cases was significantly associated with psoriasis risk. Thus, the results of the current study demonstrated that ACE I/D polymorphism significantly increased the risk of psoriasis in the Chinese population.

Genetic factors play important role in the development of psoriasis. Rajesh et al. indicated that TNF α gene -238G/A polymorphism increases the risk of developing psoriasis vulgaris among Indians [7]. Zablotna et al. suggested that the -2518 A/G MCP-1 and -403 G/A RANTES promoter gene polymorphisms may be risk factors for psoriasis [8]. Izmirlı et al. found a correlation between methylenetetrahydrofolate C677T polymorphism and psoriasis among the southern Turkish population [9]. Shi et al. demonstrate a significant association between the CARD14 rs11652075 polymorphism and psoriasis [10].

ACE I/D polymorphism also played a critical role in the development of other diseases. Kang et al. indicated that the insertion/deletion polymorphism of the ACE gene may be associated with susceptibility to COPD in the Asian population [11]. He et al. suggested that genetically-reduced serum ACE activity might be a causal risk factor for obstructive sleep apnea syndrome (OSAS) [12]. Pabalan et al. found that carriers of the ACE II genotype appear to be protected from gastric cancer [13-25].

In conclusion, the current study showed that ACE I/D polymorphism may influence the risk of psoriasis in a Chinese Han population.

References

1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. *Lancet* 2007; 370: 263-271.
2. Mee JB, Johnson CM, Morar N, Burslem F, Groves RW. The psoriatic transcriptome closely resembles that induced by interleukin-1 in cultured keratinocytes: dominance of innate immune responses in psoriasis. *Am J Pathol* 2007; 171: 32-42.
3. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. *Am J Clin Dermatol* 2003; 4: 441-447.
4. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. *J Clin Invest* 1990; 86: 1343-1346.
5. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, Soubrier F. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. *Am J Hum Genet* 1992; 51: 197-205.
6. Danser AH, Schalekamp MA, Bax WA, van den Brink AM, Saxena PR, Riegger GA, Schunkert H. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. *Circulation* 1995; 92: 1387-1388.
7. Rajesh D, Gurumurthy R, Kutty AV, Balakrishna S. Tumor necrosis factor alpha gene promoter -238G/A polymorphism increases the risk of psoriasis vulgaris in Indian patients. *Int J Dermatol* 2017; 56: 307-311.
8. Zablorna M, Sobjanek M, Purzycka-Bohdan D, Szczerkowska-Dobosz A, Nedoszytko B, Nowicki R. The -2518 A/G MCP-1 and -403 G/A RANTES promoter gene polymorphisms are associated with psoriasis vulgaris. *Clin Exp Dermatol* 2016; 41: 878-883.
9. Izmirlı M, Sen BB, Rifaioglu E, Gogebakan B, Aldemir O, Sen T, Ekiz O, Alptekin D. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in psoriasis in southern Turkey. *An Bras Dermatol* 2016; 91: 611-613.
10. Shi G, Li SJ, Wang TT, Cheng CM, Fan YM, Zhu KJ. The common CARD14 gene missense polymorphism rs11652075 (c.C2458T/p.Arg820Trp) is associated with psoriasis: a meta-analysis. *Genet Mol Res* 2016; 15.
11. Kang SW, Kim SK, Chung JH, Jung HJ, Kim KI, Kim J, Ban JY. Genetic Polymorphism of Angiotensin-Converting Enzyme and Chronic Obstructive Pulmonary Disease Risk: An Updated Meta-Analysis. *Biomed Res Int* 2016; 2016: 7636123.
12. He L, Wang B, Lang WY, Xue J, Zhao DL, Li GF, Zheng LH, Pan HM. Genetically-reduced serum ACE activity might be a causal risk factor for obstructive sleep apnea syndrome: A meta-analysis. *Sci Rep* 2015; 5: 15267.
13. Pabalan N, Jarjanazi H, Ozcelik H. Associations of the Insertion/Deletion Polymorphism in the ACE Gene and Risk of Gastric Cancer: A Meta-Analysis. *J Gastrointest Cancer* 2015; 46: 370-379.
14. Pastorino U. Lung cancer screening. *Br J Cancer*. 2010; 102: 1681-1686.
15. Sen R, Baltimore D. Inducibility of K immunoglobulin enhancer-binding protein NF-kB by a posttranslational mechanism. *Cell* 1986; 47: 921-928.
16. Chen F, Castranova V, Shi X, Demers LM. New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. *Clin Chem* 1999; 45: 7-17.
17. Sun XF, Zhang H. NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. *Histol Histopathol* 2007; 22: 1387-1398.
18. Karban AS, Okazaki T, Panhuysen CI, Gallegos T, Potter JJ, Bailey-Wilson JE, Silverberg MS, Duerr RH, Cho JH, Gregersen PK, Wu Y, Achkar JP, Dassopoulos T, Mezey E, Bayless TM, Novuet FJ, Brant SR. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. *Hum Mol Genet* 2004; 13: 35-45.
19. Song S, Chen D, Lu J, Liao J, Luo Y, Yang Z, Fu X, Fan X, Wei Y, Yang L, Wang L, Wang J. NFkB1 and NFkBIA polymorphisms are associated with increased risk for sporadic colorectal cancer in a southern Chinese population. *PLoS One* 2011; 6:e21726.
20. López-Mejías R, García-Bermúdez M, González-Juanatey C, Castañeda S, Miranda-Fillooy JA, Gómez-Vaquero C, Fernández-Gutiérrez B, Balsa A, Pascual-Salcedo D, Blanco R, González-Álvaro I, Llorca J, Martín J, González-Gay MA. NFKB1-94ATTG ins/del polymorphism (rs28362491) is associated with cardiovascular disease in patients with rheumatoid arthritis. *Atherosclerosis* 2012; 224: 426-429.
21. Mukhopadhyay T, Roth JA, Maxwell SA. Altered expression of the p50 subunit of the NF-kappa B transcription factor complex in non-small cell lung carcinoma. *Oncogene* 1995; 11: 999-1003.
22. Bours V, Dejardin E, Goujon-Letawe F, Merville MP, Castronovo V. The NF-kappa B transcription factor and cancer: high expression of NF-kappa B- and I kappa B-related proteins in tumor cell lines. *Biochem Pharmacol* 1994; 47: 145-149.
23. Yu Y, Wan Y, Huang C. The biological functions of NF-kappaB1 (p50) and its potential as an anti-cancer target. *Curr Cancer Drug Targets* 2009; 9: 566-571.
24. Maria TG, Vasileios KE, Panagiotis PS, Kostas SN. Changes of acute-phase protein levels in the serum of lung cancer patients following radiotherapy. *Int J Clin Exp Med* 2013; 6: 50-56.
25. Nikolaos T, Maria T, Ioannis KD, Georgios L, Nikolaos P, Stamatina D, Christos P, Georgios K, Vasileios B, Anna E. Dermatomyositis as an early manifestation and a significant clinical precursor of lung cancer: report of a rare case and review of the current literature. *Int J Clin Exp Med* 2013; 6: 105-109.

***Correspondence to**

Guo-Dong Huang

Department of integration of traditional and western medicine,

First Affiliated Hospital of Nanchang University

Nanchang 330006, Jiangxi

PR China